Chemotherapy of anaplastic oligodendroglial tumours

Bibliography

• MORK SJ, LINDEGAARD KF, HALVORSEN TB et al.: Oligodendroglioma: incidence and biological behavior in a defined population.Neurosurg. (1985) 63:881–889.
   Google Scholar
• RUSSELL DS, RUBINSTEIN LJ: Pathology of tumours of the nervous system. Edward Arnold (Ed.), London (1989).
   Google Scholar
• SCHIFFER D: Brain Tumors. Biology Pathology and Clinical References (2'd edn).Springer Verlag, Berlin (1996).
   Google Scholar
• COONS SW, JOHNSON PC, SCHEITHAUER BW et al: Improving diagnostic accuracy and interobserver concordance in the classification and grading of primary gliomas. Cancer (1997) 79:1381–1393.
   PubMed Web of Science ®Google Scholar
• DAUMAS-DUPORT C, VARLET P, TUCKER ML et al.: Oligodendrogliomas. Part I: patterns of growth, histological diagnosis, clinical and imaging correlations: a study of 153 cases. j. Neuro-Oncol (1997a) 34:37–59.
   Google Scholar
• KLEIHUES P, CAVANEE WK: World Health Organization classification of tumors: pathology and genetics of tumors of the nervous system. IARC Press, Lyon, France (2000):6–7.
   Google Scholar
• SHAW EG, SCHEITHAUER BW, O'FALLON JR et al: Oligodendrogliomas: the Mayo Clinic experience. Neurosurg. (1992) 76:428–434.
   Google Scholar
• LEIGHTON C, FISHER B, BAUMAN G et al.: Supratentorial low-grade glioma in adults: an analysis of prognostic factors and timing of radiation. Clin. Oncol (1997) 15:1294–1301.
   Google Scholar
• DONAHUE B, SCOTT CB, NELSON JSet al.: Influence of an oligodendroglial component on the survival of patients with anaplastic astrocytomas: a report of Radiation Therapy Oncology Group 83–02.Int Radiat Oncol Biol. Phys. (1997) 38:911–914.
   Google Scholar
• KRISTOF RA, NEULOH G, HANS V et al.: Combined surgery, radiation, and PCV chemotherapy for astrocytomas compared to oligodendrogliomas and oligoastrocytomas WHO grade III.Neuro-Oncol (2002) 59:231–237.
   Google Scholar
• WINGER MJ, MACDONALD DR, CAIRNCROSS JG: Supratentorial anaplastic gliomas in adults. The prognostic importance of extent of resection and prior low-grade glioma. I Neurosurg. (1989) 71:487–493.
   Google Scholar
• REIFENBERGER G, KROS JM, BURGER R et al.: Oligodendroglioma. In: World Health Organization Classification of Tumors: Pathology and Genetics of Tumors of the Nervous System. Kleihues P, Cavanee WK (Eds), IARC Press, Lyon, France (2000):56–64.
   Google Scholar
• GIANNINI C, SCHEITHAUER BW, WEAVER AL et al: Oligodendrogliomas: reproducibility and prognostic value of histologic diagnosis and grading. Neuropathol Exp. Neurol (2001) 60:248–262.
   PubMedGoogle Scholar
• KROS JM: Oligodendrogliomas: clinicopathological correlations. Neuro-Oncol (1995) 24:29–31.
   Google Scholar
• DAUMAS-DUPORT C, TUCKER ML, KOLLES H et al.: Oligodendrogliomas. Part II: a new grading system based on morphological and imaging criteria.Neuro-Oncol (1997b) 34:61–78.
   Google Scholar
• CAIRNCROSS JG, UEKI K,ZLATESCU MC et al.: Specific chromosomal losses predict chemotherapeutic response and survival in patients with anaplastic oligodendrogliomas. J. Natl. Cancer Inst. (Bethesda) (1998) 90:1473–1479.
   Google Scholar
• •First paper reporting the association between lp/19q loss and response to chemotherapy in anaplastic oligodendrogliomas.
   Google Scholar
• REIFENBERGER G, LOUIS DN: Oligodendroglioma: toward molecular definitions in diagnostic neuro-oncology. Neuropathol Exp. Neurol (2003) 62(2):111–126.
   PubMed Web of Science ®Google Scholar
• ••A thorough review regarding the usefulnessof molecular diagnosis in neuro-oncology.
   Google Scholar
• ZLATESCU MC, YAZDI AT, SASAKI H et al.: Tumor location and growth pattern correlate with genetic signature in oligodendroglial neoplasms. Cancer Res. (2001) 61:6713–6715.
   PubMed Web of Science ®Google Scholar
• REIFENBERGER G, KROS JM, BURGER R et al: Oligoastrocytoma. In: World Health Organization Classification of Tumors: Pathology and Genetics of Tumors of the Nervous System. Kleihues P, Cavanee WK (Eds), IARC Press, Lyon (2000):65–69.
   Google Scholar
• SMITH JS, PERRY A, BORELL TJ et al.: Alterations of chromosome arms lp and 19q as predictors of survival in oligodendrogliomas, astrocytomas, and mixed oligoastrocytomas. j Clin. Oncol (2000) 18:636–645.
   PubMed Web of Science ®Google Scholar
• INO Y, BETENSKY RA, ZLATESCU MC et al.: Molecular subtypes of anaplastic oligodendroglioma: implications for patient management at diagnosis. Clin. Cancer Res. (2001) 7:839–845.
   PubMed Web of Science ®Google Scholar
• ••A molecular analysis identifies subtypes ofanaplastic oligodendrogliomas with different response to chemotherapy and survival.
   Google Scholar
• NUTT CL, MANI DR, BETENSKY RA et al: Gene expression-based classification of malignant gliomas correlates better with survival than histological classification. Cancer Res. (2003) 63:1602–1607.
   PubMed Web of Science ®Google Scholar
• •Study suggesting that gene-expression based classification provides a more accurate predictor of prognosis in non-classic malignant gliomas than conventional pathological classification.
   Google Scholar
• ENGELHARD HH: Current diagnosis and treatment of oligodendroglioma. Neurosurg. Focus (2002) 12(2):1–7.303
   Google Scholar
• BERGER MS, ROSTOMILY RC: Low grade gliomas: functional mapping resection strategies, extent of resection, and outcome. Neurooncol (1997) 34:85–101.
   PubMed Web of Science ®Google Scholar
• HENDERSON KH, SHAW EG: Randomized trials of radiation therapy in adult low-grade gliomas. Semin. Radiat Oncol (2001) 11:145–151.
   PubMedGoogle Scholar
• DEHGHANI F, SCHACHENMAYR W, LAUN A et al.: Prognostic implication of histopathological, immunohistochemical and clinical features of oligodendrogliomas: a study of 89 cases. Acta Neuropathol (1998) 95:493–504.
   PubMedGoogle Scholar
• BOIARDI A, SILVANI A, POZZI A et al.:Advantage of treating anaplastic gliomas with aggressive protocol combining chemotherapy and radiotherapy.Neuro-Oncol (1997) 34:179–185.
   Google Scholar
• WALKER MD AE, HUNT WE, MACCARTY CS et al.: Evaluation of BCNU and/or radiotherapy in the treatment of anaplastic gliomas.Neurosurg. (1978) 49:333–343.
   Google Scholar
• WALKER MD GS, BYAR DP, ALEXANDER E et al.: Randomized comparison of radiotherapy and nitrosoureas for the treatment of malignant glioma after surgery. N Engl. I Med. (1980) 303:1323–1329.
   PubMedGoogle Scholar
• LEIBEL SA, SCOTT CB, JS I.:Contemporary approaches to the treatment of malignant gliomas with radiation therapy. Semin Oncol (1994) 21:198–219.
   Google Scholar
• SHAW EG, SCHEITHAUER BW, O'FALLON JR et al.: Mixed oligoastrocytomas: a survival and prognostic factor analysis. Neurosurgery (1994) 34:577–582.
   Google Scholar
• CELLI P, NOFRONE I, PALMA L et al:Cerebral oligodendroglioma: prognostic factors and life history. Neurosurgery (1994) 35:1018–1035.
   PubMed Web of Science ®Google Scholar
• ALLISON RR, SCHULSINGER A, VON GTAMA V et al.: Radiation and chemotherapy improve outcome in oligodendroglioma. Int. Radiat. Oncol Biol. Phys. (1997) 37(2):399–403.
   Google Scholar
• CROSSEN JR, GARWOOD D, GLASTEIN E et al.: Neurobehavioral sequelae of cranial irradiation in adults. A review of radiation-induced encephalopathy.j. Clin. Oncol (1994) 12:627–642.
   PubMed Web of Science ®Google Scholar
• OLSON JD, RIEDEL E,DEANGELIS LM: Long-term outcome oflow-grade oligodendroglioma and mixed glioma. Neurology (2000) 54:1442–1448.
   PubMed Web of Science ®Google Scholar
• KLEINBERG L, WALLNER K,MALKIN MG: Good performance status of long-term disease-free survivors of intracranial gliomas. hat. J. Radiat. Oncol Biol. Phys. (1993) 26:129–133.
   PubMed Web of Science ®Google Scholar
• SURMA-AHO 0, NIEMELA M, VILKKI J et al.: Adverse long-term effects of brain radiotherapy in adult low-grade glioma patients. Neurology (2001) 56:1285–1290.
   Google Scholar
• BROWN PD, BUCKNER JC, O'FALLON JR et al.: Effects of radiotherapy on cognitive function in patients with low-grade glioma measured by the Folstein Mini-Mental State Examination. J. Clin. Oncol (2003) 21:2519–2524.
   Google Scholar
• TAPHOORN MJB, SCHIPHORST AK, SNOEK FJ: Cognitive functions and quality of life in patients with low-grade gliomas: the impact of radiotherapy. Ann. Neurol (1994) 36:48–54.
   PubMedGoogle Scholar
• KLEIN M. HEIMANS JJ,AARONSON NK et al.: Effect of radiotherapy and other treatment-related factors on mild-term cognitive sequelae in low-grade gliomas: a comparative study. Lancet (2002) 360:1361–1368.
   Google Scholar
• TAYLOR BV, BUCKNER JC, CASCINO TL et al.: Effects of radiation and chemotherapy on cognitive function in patients with high-grade glioma. .1 Oncol (1998) 16(6):2195–2201.
   Google Scholar
• SUNYACH MP, POMMIER P, MARTEL LAFAY I et al.: Conformal irradiation for pure and mixed oligodendroglioma: the experience of Centre Leon Berard Lyon. Int. I Radiat. Oncol Biol. Phys. (2003) 56(1):296–303.
   Google Scholar
• •First report of conformal radiotherapy in oligodendrogliomas.
   Google Scholar
• BAUMAN GS, CAIRNCROSS JG: Multidisciplinary management of adult anaplastic oligodendrogliomas and anaplastic mixed oligo-astrocytomas. Semin. Radiat Oncol (2001) 11(2):170–180.
   PubMedGoogle Scholar
• •An extensive review on the management of anaplastic oligodendrogjial tumours.
   Google Scholar
• MASON WP, LOUIS DN, CAIRNCROSS JG: Chemosensitive gliomas in adults: which ones and why? Oncol (1997) 15(12):3423–3426.
   Google Scholar
• CAIRNCROSS JG, MACDONALD DR: Successful chemotherapy for recurrentmalignant oligodendroglioma. Ann. Neurol (1988) 23:460–464
   Google Scholar
• MACDONALD DR, O'BRIEN RA, GILBERT JJ et al.: Metastatic anaplastic oligodendroglioma. Neurology (1989) 39:1593–1596.
   Google Scholar
• CAIRNCROSS JG, MACDONALD DR, RAMSAY DA: Aggressive oligodendroglioma: a chemosensitive tumor. Neurosurgery (1992) 31(1):78–82.
   PubMed Web of Science ®Google Scholar
• CAIRNCROSS JG, MACDONALD D, LUD WIN S et al.: Chemotherapy for anaplastic oligodendroglioma. .1. Clin. Oncol (1994) 12:2013–2021.
   Google Scholar
• •The first Phase II study describing the efficacy of PCV in anaplastic oligodendrogliomas.
   Google Scholar
• KIM L, HOCHBERG FH,THORNTON AF et al.: Procarbazine, lomustine, and vincristine (PCV) chemotherapy for Grade III and Grade IV oligoastrocytomas. Neurosurg. (1996) 85:602–607.
   Google Scholar
• SOFFIETTI R, RUDA' R, BRADAC GB et al.: PCV chemotherapy for recurrent oligodendrogliomas and oligoastrocytomas. Neurosurgery (1998) 43:1066–1073.
   Google Scholar
• •The first Phase II study describing the efficacy of PCV in recurrent/progressive originally low-grade oligodendrogjial tumours.
   Google Scholar
• VAN DEN BENT MJ, KROS JM, HEIMANS JJ et al.: Response rate and prognostic factors of recurrent oligodendroglioma treated with procarbazine, CCNU, and vincristine chemotherapy. Neurology (1998) 51:1140–1145.
   Google Scholar
• CAIRNCROSS JG, MACDONALD DR:Chemotherapy for oligodendroglioma: Progress report. Arch. Neurol (1991) 48:225–227.
   PubMed Web of Science ®Google Scholar
• BROWN M, CAIRNCROSS JG, VICK NA et al.: Differential response of recurrent oligodendroglioma versus astrocytoma to intravenous melphalan.Proceedings of the American Academy of Neurology Neurology (1990) 40:397.
   Google Scholar
• PETERSON K, PALEOLOGOS N, FORSYTH P et al: Salvage chemotherapy for oligodendroglioma. Neurosurg. (1996) 85:597–601.
   Google Scholar
• CHAMBERLAIN MC, KORMANIK PA: Salvage chemotherapy with paclitaxel for recurrent oligodendrogliomas. .1. Clin. Oncol (1997) 15:3427–3432.
   PubMed Web of Science ®Google Scholar
• CHAMBERLAIN MC: Salvage chemotherapy with CPT-11 for recurrent oligodendrogliomas. j Neuro-Oncol (2002) 59:157–163.
   PubMed Web of Science ®Google Scholar
• POISSON M, PEREON Y, CHIRAS J et al.: Treatment of recurrent malignant supratentorial gliomas with carboplatin (CBDCA). I Neuro-Oncol (1991) 10:139–144.
   PubMed Web of Science ®Google Scholar
• FRIEDMAN HS, LOVELL S,RASHEED K et al.: Treatment of adults with progressive oligodendroglioma with carboplatin (CBDCA): preliminary results. Med. Pediatr. Oncol (1998) 31:16–18.
   Google Scholar
• SOFFIETTI R, NOBILE M, RUDA' R et al.: Second-line chemotherapy with carboplatin in recurrent/progressive oligodendroglial tumors after PCV (procarbazine, lomustine and vincristine): a Phase II study. Cancer (2004) (In Press).
   Google Scholar
• STEWART DJ, DAHROUGE S,SOLTYS K: A Phase II study of 5-fluorouracil plus folinic acid in malignant gliomas in adults. J. Neuro-Oncol (1995) 23:249–252.
   PubMedGoogle Scholar
• FRIEDMAN H, MCLENDON R, KERBY T et al.: DNA mismatch repair and 06-alkylguanine-DNA alkyltransferase analysis and response to temodal in newly diagnosed malignant glioma. I Clin. Oncol. (1998) 16:3851–3857.
   PubMed Web of Science ®Google Scholar
• YUNG WK, PRADOS MD,YAYA-TUR R et al.: Multicenter Phase II trial of temozolomide in patients with anaplastic astrocytoma or anaplastic oligoastrocytoma at first relapse: Temodal Brain Tumor Group. I Clin. Oncol (1999) 17:2762–2771.
   Google Scholar
• YUNG WK, ALBRIGHT RE, OLSON J et al.: A Phase II study of temozolomide versus procarbazine in patients with glioblastoma multiforme at first relapse. Br. .1. Cancer (2000) 83:588–593.
   Google Scholar
• BRADA M, HOANG-XUANG K, RAMPLING R et al.: Multicenter Phase II trial of temozolomide in patients with glioblastoma multiforme at first relapse. Ann. Oncol (2001) 12:259–266.
   PubMed Web of Science ®Google Scholar
• DINNES J, CAVE C, HUANG S et al.: A rapid and systematic review of the effectiveness of temozolomide for the treatment of recurrent malignant glioma. Br. J. Cancer (2002) 86:501–505.
   PubMed Web of Science ®Google Scholar
• CHINOT 0, HONORE S, DUFOUR H et al.: Safety and efficacy of temozolomide in patients with recurrent anaplastic oligodendrogliomas after standardradiotherapy and chemotherapy. I Clin. Oncol (2001) 19:2449–2455.
   Google Scholar
• •The largest series on the efficacy of second-line temozolomide in anaplastic oligodendroglial tumors.
   Google Scholar
• VAN DEN BENT MJ,KEIME-GUILBERT F, BRANDES AA et al.: Temozolomide chemotherapy in recurrent oligodendroglioma.Neurology (2001) 57:340–342.
   Google Scholar
• SOFFIETTI R, COSTANZA A,NOBILE M et al: Temozolomide in recurrent/progressive oligodendroglioma and oligoastrocytoma: a Phase II study. Proceedings of the 51-h Annual Meeting of the American Academy of Neurology Denver, USA (2002):506.003.
   Google Scholar
• VAN DEN BENT MJ, CHINOT 0, BOOGERD W et al: Second-line chemotherapy with temozolomide in recurrent oligodendroglioma after PCV (procarbazine, lomustine and vincristine) chemotherapy: EORTC Brain Tumor Group Phase II study 26972. Ann. Oncol (2003) 14:599–602.
   PubMedGoogle Scholar
• VAN DEN BENT MJ,TAPHOORN MJB, BRANDES AA et al: Phase II study of first-line chemotherapy with temozolomide in recurrent oligodendroglial tumors: the European Organization for Research and Treatment of Cancer Brain Tumor Group study 26971.Clin. Oncol (2003) 21:2525–2528.
   Google Scholar
• •The first Phase II study reporting the efficacy of first-line temozolomide in oligodendroglial tumors.
   Google Scholar
• SAARINEN UM, PIHKO H, MAKIPERNAA A: High-dose thiotepa with autologous bone marrow rescue in recurrent malignant oligodendroglioma: a case report. Neuro-Oncol (1990) 9:57–61.
   Google Scholar
• CAIRNCROSS JG, SWINNEN L, BAYER R et al.: for the Oligodendroglioma Study Group: Myeloablative chemotherapy for recurrent aggressive oligodendroglioma. Neuro-Oncology (2000) 2:114–119.
   PubMedGoogle Scholar
• ABREY LE, CHILDS BH,PALEOLOGOS N et al.: High-dose chemotherapy with stem cell rescue as initial therapy for anaplastic oligodendroglioma. .1. Neurooncol. (2003) 65(2):127–134.
   Google Scholar
• KYRITSIS AP, YUNG WKA, BRUNER Jet al.: The treatment of anaplastic oligodendrogliomas and mixed gliomas. Neurosurgery (1993) 32:365–371.
   Google Scholar
• JEREMIC B, SHIBAMOTO Y,GRUIJICIC D et al.: Combined treatment modality for anaplastic oligodendroglioma:a Phase II study. I Neuro-Oncol (1999) 43(2):179–85.
   Google Scholar
• KIRBY S, MACDONALD DR, FISHER B et al.: Pre-radiation chemotherapy for malignant glioma in adults. Can. I Neurol Sci. (1996) 23:123–127.
   Google Scholar
• PALEOLOGOS N, MACDONALD DR, VICK NA et al.: Neoadjuvant procarbazine, CCNU, and vincristine for anaplastic and aggressive oligodendroglioma.Neurology (1999) 53:1141–1143.
   PubMed Web of Science ®Google Scholar
• •A study suggesting that the duration of response after neoadjuvant chemotherapy followed by consolidation radiotherapy is longer than after neoadjuvant chemotherapy alone.
   Google Scholar
• STREFFER J, SCHABET M,BAMBERG M et al: A role for preirradiation PCV chemotherapy for oligodendroglial brain tumors. I Neurol (2002) 247:297–302.
   Google Scholar
• FORTIN D, MACDONALD DR, STITT L et al.: PCV for oligodendroglial tumors: in search of prognostic factors for response and survival. Can. I Sci.(2001) 28:215–223.
   Google Scholar
• BAUMAN GS, INO Y, UEKI K et al: Allelic loss of chromosome lp and radiotherapy plus chemotherapy in patients with oligodendrogliomas. bit. I Radiat. Oncol Biol. Phys. (2000) 48:825–830.
   PubMed Web of Science ®Google Scholar
• CHALAVI A, KANNER A, PEEREBOOM D et al.: Impact of chromosome lp status in response of oligodendroglioma to temozolomide: preliminary results. I Neuro-Oncol (2003) 61:267–273.
   PubMedGoogle Scholar
• THIESSEN B, MAGUIRE JA,MCNEIL K et al.: Loss of heterozygosity for loci on chromosome lp and 10q in oligodendroglial tumors: relationship to outcome and chemosensitivity.Neuro-Oncol (2003) 64:271–278.
   Google Scholar
• BETENSKY RA, LOUIS DN, CAIRNCROSS JG: Influence of unrecognized molecular heterogeneity on randomized clinical trials. I Clin. Oncol (2002) 20:2495–2499.
   PubMed Web of Science ®Google Scholar
• NUUTINEN J, SONNINEN P, LEHIKOINEN P et al.: Radiotherapy treatment planning and long-term follow-up with [(11)Clmethionine PET in patients with low-grade astrocytoma. bit. I Radiat. Oncol Biol. Phys. (2000) 48(1):43–52.
   PubMedGoogle Scholar
• MCKNIGHT TR, VON DEM BUSSCHE MH, VIGNERON DB et al: Histopathological validation of a three-dimensional magnetic resonance spectroscopy index as a predictor of tumor presence. .1 Neurawrg. (2002) 97(0794–802.
   Google Scholar